Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0CDYJL
ADC Name
MYTX-011
Synonyms
MYTX 011; MYTX011
   Click to Show/Hide
Organization
Mythic Therapeutics, Inc.
Drug Status
Phase 1
Indication
In total 1 Indication(s)
Non-small cell lung cancer [ICD11:2C25]
Phase 1
Drug-to-Antibody Ratio
2
Antibody Name
Undisclosed
Antigen Name
Hepatocyte growth factor receptor (MET)
  Antigen Info 
Payload Name
Undisclosed
Linker Name
Undisclosed
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type NCT Number Clinical Status Clinical Trial Description
Undisclosed  NCT05652868
Phase 1
A phase 1 multicenter dose escalation and dose expansion study of antibody-drug conjugate MYTX-011 in subjects with non-small cell lung cancer - kismet-01.
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Related Clinical Trial
NCT Number NCT05652868  Clinical Status Phase 1
Clinical Description A phase 1 multicenter dose escalation and dose expansion study of antibody-drug conjugate MYTX-011 in subjects with non-small cell lung cancer - kismet-01.
References
Ref 1 A Phase 1 Multicenter Dose Escalation and Dose Expansion Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer - KisMET-01, NCT05652868

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.